The aims of this study were to (A) clarify whether brain leptin levels are affected during the progression of AD, (B) investigate the relationship between CSF leptin levels and hippocampal volume, AD biomarkers, such as Aβ, total-tau (t-tau), phospho-tau (p-tau) and inflammatory markers. The gene discussed is MAPT; the disease is Alzheimer disease.